HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody drug shows promise for Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to treatment. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to find the best dose and see how well…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 23, 2026 19:16 UTC
-
New oral drug ICP-248 enters human trials for blood cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ICP-248, taken as a pill, for people with B-cell blood cancers like leukemia and lymphoma. The study will see if the drug is safe, what dose works best, and whether it helps shrink tumors. About 191 adults aged 18 to 80 are…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 19:16 UTC
-
Can a lower dose of chemo drug improve life after transplant for older cancer patients?
Disease control Recruiting nowThis study tests whether a lower dose of the drug cyclophosphamide, combined with sirolimus, can prevent graft-versus-host disease (GVHD) after a stem cell transplant in people aged 60 and older with blood cancers. The goal is to see if the lower dose improves quality of life com…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New pill HMPL-506 enters human trials for leukemia
Disease control Recruiting nowThis early-stage study tests an experimental pill called HMPL-506 in about 132 adults with certain blood cancers (leukemias) that have come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink or control …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
New drug DS3790a enters human trials for blood cancers
Disease control Recruiting nowThis study tests a new drug called DS3790a in people with blood cancers. The goal is to check its safety and how well it works, alone or with other treatments. About 420 adults will take part. The study is currently recruiting.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 16, 2026 12:50 UTC
-
Massive study aims to unlock secrets of early blood cancers
Knowledge-focused Recruiting nowThis study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:54 UTC
-
15-Year watch begins for CAR T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guide…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: Lakefront Biotherapeutics NV • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:29 UTC